Category: Cardiometabolic
-
Blocking the Clot Is Not Protecting the Brain: An Unpeer-Reviewed UK Biobank Preprint on Atrial Fibrillation and Brain Health (n=502,099)
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The paper discussed below is a medRxiv preprint (v1, posted 2026-08-12) that has not yet been peer-reviewed. It is an observational cohort analysis with Mendelian randomization as a secondary…
-
A million exomes point at FNIP1 — and at how narrow the window for hitting it may be
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. An exome-sequencing analysis of 1,032,116 people across America, Europe and Asia tested rare protein-coding variants against the triglyceride-to-HDL ratio, used as a biomarker of energy state…
-
Finerenone across CKM stages — the relative effect is flat, the absolute benefit is not, and the new endpoint moves its own goalposts
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. A post hoc analysis of 12,990 people with type 2 diabetes and chronic kidney disease from two phase 3 trials, pooled and then re-classified using the…
-
Retatrutide in early type 2 diabetes — the glucose axis converges, the weight axis does not
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In 537 adults with early type 2 diabetes inadequately controlled on diet and exercise (mean duration 2.5 years, HbA1c 7.9%, BMI 35.8), 40 weeks of once-weekly…
-
MASLD non-invasive tests — fibrosis staging clears the bar, the MASH treatment gate does not
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In a prospective, multicenter cohort with centrally read liver biopsy as the reference standard (LITMUS Imaging Study, N = 357, Nature Medicine, published online July 24,…
-
Does lowering Lp(a) actually cut cardiovascular events? The outcome trials — HORIZON, OCEAN(a) and ACCLAIM — and why the first readout is still not in
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Earlier parts of this series established that Lp(a) is causal (Mendelian randomization), genetically fixed, and now pharmacologically lowerable by 80–90%+ with siRNA/ASO/oral agents. But biomarker…
-
Lowering Lp(a) is a solved problem — the RNA pipeline now competes on durability, not on depth
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Four nucleic-acid drugs that shut down hepatic apo(a) production — one antisense oligonucleotide (pelacarsen) and three siRNAs (olpasiran, lepodisiran, zerlasiran) — have already saturated the depth…
-
The clinical cost behind the GLP-1 headline — reading lean-mass loss, discontinuation, rebound, and safety signals by evidence tier
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. The GLP-1/GIP headline of −15 to −20% body weight comes with clinical costs: loss of lean (fat-free) mass, real-world discontinuation (roughly 50%+ within a year),…
-
The GLP-1 commercial map (Part 3): not “who wins” but “who gets access” — the Novo–Lilly duopoly and the access bottleneck
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. In the 2025–26 GLP-1 commercial map, US prescription share has flipped: Lilly (tirzepatide) overtook Novo (semaglutide) — roughly 57%+ vs 43% of US scripts as of Q3 2025 (press…
-
The next-generation obesity pipeline: from “how much you lose” to “at what cost”
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The next-generation obesity drugs push weight-loss efficacy along three vectors: triple agonists (retatrutide), oral small molecules (orforglipron), and amylin combinations (CagriSema). At the top end, retatrutide’s…
Uthando Nethemba 